[1] Castro Dopico X, Ols S, Loré K, Karlsson Hedestam GB. Immunity to SARS-CoV-2 induced by infection or vaccination. J Intern Med 2022;291(1):32 − 50. http://dx.doi.org/10.1111/joim.13372.
[2] Cao YL, Yisimayi A, Jian FC, Song WL, Xiao TH, Wang L, et al. BA. 2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 2022;608(7923):593 − 602. http://dx.doi.org/10.1038/s41586-022-04980-y.
[3] Cao YL, Wang J, Jian FC, Xiao TH, Song WL, Yisimayi A, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature 2022;602(7898):657 − 63. http://dx.doi.org/10.1038/s41586-021-04385-3.
[4] Cao YL, Su B, Guo XH, Sun WJ, Deng YQ, Bao LL, et al. Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells. Cell 2020;182(1):73 − 84.e16. http://dx.doi.org/10.1016/j.cell.2020.05.025.
[5] Cao YL, Jian FC, Zhang ZY, Yisimayi A, Hao XH, Bao LL, et al. Rational identification of potent and broad sarbecovirus-neutralizing antibody cocktails from SARS convalescents. Cell Rep 2022;41(12):111845. http://dx.doi.org/10.1016/j.celrep.2022.111845.
[6] Du S, Cao YL, Zhu QY, Yu P, Qi FF, Wang GP, et al. Structurally resolved SARS-CoV-2 antibody shows high efficacy in severely infected hamsters and provides a potent cocktail pairing strategy. Cell 2020;183(4):1013 − 23.e13. http://dx.doi.org/10.1016/j.cell.2020.09.035.
[7] Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B. 1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet 2022;399(10332):1303 − 12. http://dx.doi.org/10.1016/S0140-6736(22)00462-7.
[8] Agrawal U, Bedston S, McCowan C, Oke J, Patterson L, Robertson C, et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. Lancet 2022;400(10360):1305 − 20. http://dx.doi.org/10.1016/S0140-6736(22)01656-7.
[9] McMenamin ME, Nealon J, Lin Y, Wong JY, Cheung JK, Lau EHY, et al. Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study. Lancet Infect Dis 2022;22(10):1435 − 43. http://dx.doi.org/10.1016/S1473-3099(22)00345-0.